Sir,
C. Andrade in his letter published in the Indian Journal of Psychiatry Vol 38, No.2 Page 117, has suggested that non responsiveness to ECT should also be considered an additional pre-requisite for patients who are to receive clozapine. For the reference of the readers of Indian Journal of Psychiatry, I would like to mention the views of some of the foreign authors on this issue. The clinical response to ECT in schizophrenia is inversely proportional to duration of symptoms and treatment resistant patients rarely respond to ECT (Saizman 1980) . The use of ECT combined with a standard neuroleptic in treatment resistant cases has been suggested as an alternative regimen (Gujavarty 1987) . Meltzer (1990) has suggested for a controlled clinical trial of ECT plus neuroleptic Vs clozapine or perhaps even ECT plus clozapine in treatment resistent schizophrenic patients. My own experience with ECT does not favour it's use in chronic schizophrenia (Pandey 1967 (Andrade, 1996) . I have the following specific responses to his comments :
a) The remarks of Saizman (1980) on the inverse relationship between duration of schizophrenic illness and responsivity to ECT are opinions based on the literature that he reviewed, and apply to chronic/ residual states. Salzman's views therefore do not contradict my stance that a trial of ECT should be considered before clozapine is prescribed for severe, positive symptom, treatment -resistant schizophrenia, where the clinical picture is altogether different.
Even if responsivity to ECT does prove low, given the favourable cost -risk -benefit ratio with ECT as compared with that of clozapine, an ECT trial remains indicated. Finally, it must be remembered that the goal of treatment is not a cure ; attenuation of symptoms by as little as 20% may be sufficient to define treatment response, for in treatment -resistant patients any improvement, however small, is a bonus (Kane, 1988) . b) When ECT has been used in patients who have responded poorly to drugs alone, in both controlled studies and case reports the existing schedule of neuroleptic medication has conventionally been continued (for review, see Andrade, 1993; Fink and Sackeim, 1996) ; in the absence of research on ECT alone for drug -resistant positive symptoms, the ECT -neuroleptic combination is advocated. c) A direct comparison of ECT + neuroleptic vs clozapine for treatment -resistant, positive symptom schizophrenia is certainly required. Until such a trial is conducted, clinicians must perforce depend upon extrapolations from existing studies.
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